http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
STANDARDS PRISM (2) 표준시론(時論) - 전기자동차와 기술표준 -전기자동차 개발과 실용화에 뒤처지지 않으려면 표준화 선행돼야
허훈,Heo, Hun 기술표준원 2011 기술표준 Vol.114 No.-
대체에너지 개발과 탄소에너지 규제에 발맞추기 위한 전기자동차의 개발과 실용화가 전 세계적으로 가속화되고 있다. 이번 8월호에서는 허훈 전기자동차 국가표준 코디네이터로부터 전기자동차의 개요와 현황, 세계 각국의 동향과 표준화작업의 필요성에 대해 알아본다. 2012년 2월호에 게제될 다음 연재에서는 전기자동차의 표준화작업과 연구개발 실태와 현황에 관해 보다 자세히 소개할 예정이다.
허훈,안창욱,변철수,신호정,김영배,손상용,한상욱 대한위암학회 2017 Journal of gastric cancer Vol.17 No.3
Purpose: Although Roux-en-Y (R-Y) reconstruction after distal gastrectomy has several advantages, such as prevention of bile reflux into the remnant stomach, it is rarely used because of the technical difficulty. This prospective randomized clinical trial aimed to show the efficacy of a novel method of R-Y reconstruction involving the use of 2 circular staplers by comparing this novel method to Billroth-I (B-I) reconstruction. Materials and Methods: A total of 118 patients were randomly allocated into the R-Y (59 patients) and B-I reconstruction (59 patients) groups. R-Y anastomosis was performed using two circular staplers and no hand sewing. The primary end-point of this clinical trial was the reflux of bile into the remnant stomach evaluated using endoscopic and histological findings at 6 months after surgery. Results: No significant differences in clinicopathological findings were observed between the 2 groups. Although anastomosis time was significantly longer for the patients of the R-Y group (P<0.001), no difference was detected between the 2 groups in terms of the total surgery duration (P=0.112). Endoscopic findings showed a significant reduction of bile reflux in the remnant stomach in the R-Y group (P<0.001), and the histological findings showed that reflux gastritis was more significant in the B-I group than in the R-Y group (P=0.026). Conclusions: The results of this randomized controlled clinical trial showed that compared with B-I reconstruction, R-Y reconstruction using circular staplers is a safe and feasible procedure. This clinical trial study was registered at www.ClinicalTrials.gov (registration No. NCT01142271).